Lv52
922 积分 2023-08-09 加入
First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial
9小时前
已完结
Conversion surgery following zolbetuximab-based chemotherapy for CLDN18.2-positive gastroesophageal junction cancer
6天前
已完结
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons
8天前
已完结
Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer
15天前
已完结
Outcomes of Conversion Surgery vs Conventional Systemic Therapy in Stage IV Gastric Cancer: A Systematic Review and Meta-Analysis
16天前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/ gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
19天前
已完结
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study
21天前
已完结
Conversion Surgery After Trastuzumab‑Based Chemotherapy and Immunotherapy for Stage IV HER2‑Positive Gastric Cancer: A Retrospective Multicenter Cohort Study
21天前
已完结
Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial
29天前
已完结
皖公网安备34019202002308
